PLT Health Solutions, Inc. has received a license from the Natural and Non-Prescription Health Products Directorate (NNHPD) from Health Canada to market its ingredient AlvioLife to support respiratory health in Canada.
 
AlvioLife is a proprietary composition of extracts sourced from Boswellia serrata gum resin, standardized to 30% 3-O-acetyl-11-keto-beta boswellic acid (AKBA), and Aegle marmelos dried fruit, which is designed to support respiratory health. Clinical trials on the product have yielded positive findings in the ingredient’s capacity to improve overall respiratory health, maintain clear airways, help against environmental exposure and soothe respiratory issues.
 
In Canada, the approved claims include “AlvioLife helps to support lower respiratory tract health,” and “AlvioLife helps to support lower respiratory tract health that includes the bronchial tubes and the lungs’ health.”
 
Dr. Barbara Davis, head of clinical and regulatory sciences for PLT Health Solutions, said the granting of an NHP license by Health Canada is a significant milestone for AlvioLife, both because it opens up the Canadian market for this unique ingredient, and for what it says about the science that supports AlvioLife’s health claims.
 
“Respiratory health is at the top of everyone’s minds these days,” Davis said. “AlvioLife is an interesting ingredient both as a standalone but also as a compliment to immune support ingredients. The anti-inflammatory effects, particularly 5-lipoxygenase inhibition by AKBA and quince fruit, are responsible for its effectiveness in supporting respiratory health. Accumulating and significant evidence suggests that 5-LOX has profound influence on the onset and progression of airway inflammation.”
 
A 56-day, randomized, double-blind clinical trial, published in the journal Phytotherapy Research, found that a daily dose of 200 mg AlvioLife resulted in statistically significant improvements in a group of 36 participants in several areas of respiratory health compared to those receiving a placebo.
 
Response to environmental stimuli and breathing scores were significantly better in the AlvioLife group compared to the placebo group, including a significant improvement in peak expiratory flow, which improved over 56 days in the experimental group but not in the placebo group. Additionally, the experimental group saw improvements in quality of life assessments compared to placebo, in areas including activity limitation and emotional function, which significantly improved on day 14 but then further improved on days 28 and 56.